GlassScriptPhysician profile
David L Bejot
NPI 1588668222
$4,825.55
in general payments reported to CMS, 2019-2025
30 companies · $1,095 in 2025
The $1,095 reported for 2025 was more than what 92% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $373 · 2020: $56.22 · 2021: $415 · 2022: $964 · 2023: $747 · 2024: $1,175 · 2025: $1,095.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,918 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,917.63 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $593.22 | 2019-2025 | Rocklatan, Clareon, Hydrus Microstent |
| Sun Pharmaceutical Industries INC. | $559.32 | 2019-2025 | |
| Abbvie INC. | $532.53 | 2024-2025 | |
| Biotissue Holdings INC. | $482.95 | 2021-2024 | |
| Mallinckrodt Hospital Products INC. | $476.80 | 2021-2025 | Acthar |
| Amgen INC. | $416.99 | 2024-2025 | Tepezza |
| Horizon Therapeutics Plc | $220.99 | 2021-2023 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $202.26 | 2024-2025 | Xdemvy |
| Dompe US, INC. | $170.90 | 2021-2025 | Oxervate |
| Sight Sciences, INC. | $170.11 | 2019-2025 | Tearcare System |
| Bausch & Lomb Americas INC. | $125.68 | 2024-2025 | Xiidra, Miebo, Vyzulta |
| Kala Pharmaceuticals, INC. | $103.69 | 2021 | |
| Aerie Pharmaceuticals, INC. | $89.41 | 2019 | |
| Allergan, INC. | $84.78 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $82.39 | 2019-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $81.13 | 2022-2023 | |
| Glaukos Corporation | $75.78 | 2025 | Istent Infinite, Idosetr |
| Thea Pharma INC. | $59.44 | 2023-2025 | Iyuzeh |
| Astellas Pharma US INC | $50.97 | 2024-2025 | Izervay |
| Ocular Therapeutix, INC. | $43.70 | 2024 | Dextenza |
| Optos, INC. | $35.71 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $27.92 | 2022 | |
| Rayner Intraocular Lenses Limited | $26.11 | 2024 | Rayone Spheric, Omidria, Rayone Aspheric |
| Apellis Pharmaceuticals, INC. | $22.09 | 2025 | Syfovre |
| Oyster Point Pharma, INC. | $20.00 | 2023 | Tyrvaya |
| Alimera Sciences, INC. | $18.69 | 2022 | |
| Tearlab Corp | $14.16 | 2021 | |
| Genentech USA, INC. | $14.15 | 2019 | |
| Shire North American Group INC | $13.31 | 2019 | |
| New World Medical,INC. | $10.37 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Bejot listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.